National Science Foundation

Remedium Bio is a Boston-based gene therapy company dedicated to developing curative treatments for a variety of debilitating conditions. The company employs a unique approach that combines established technologies in innovative ways to address well-defined disease mechanisms. By modularly applying these proven technologies, Remedium Bio focuses on creating localized and targeted therapies centered on clinically validated molecules and pathways. Its pipeline includes leading gene therapy candidates in multiple fields, such as rheumatology, endocrinology, and neurology, aimed at providing effective treatments for a range of immune, age-related, and metabolic disorders.

GENASSIST is a genetics company that provides assisted reproductive technology genetic consultation and testing services.

Protabit is a protein engineering company focused on developing innovative solutions for industrial, agricultural, and healthcare applications. The company utilizes a proprietary platform that integrates computational modeling, high-throughput screening, and directed evolution to enhance the diversity of protein sequences. This advanced approach allows Protabit to create novel proteins tailored to meet specific client needs. The company's efforts are further strengthened through a strategic partnership with the Monsanto Company and the California Institute of Technology, positioning Protabit at the forefront of the protein design field.

EzraBio is a biotechnology company focused on enhancing ribosome profiling for researchers across various biological samples. The company specializes in RNA adenylation technology, which facilitates efficient and rapid cDNA library construction. By offering streamlined services that encompass sample preparation and deep sequencing, EzraBio aims to simplify the ribosome profiling process. This innovative approach allows medical professionals to uncover hidden coding potential, analyze translational responses, identify tumor-associated antigens, and advance mRNA therapeutics. Through its cutting-edge solutions, EzraBio supports researchers in their quest to deepen understanding of complex biological mechanisms.

Canomiks is a company that specializes in genomics, bioinformatics, and artificial intelligence to support the development of safe and effective products in the functional food and beverage, dietary supplement, and skincare sectors. The company operates a technology platform that employs omics science, data analytics, machine learning, and bioinformatics to validate and certify the biological efficacy and safety of various ingredients and formulations. This innovative approach enables clients to create high-quality products while significantly reducing both the time and costs associated with product development. Canomiks aims to revolutionize the industry by advancing the concept of food as medicine, aligning with a long-term vision of enhancing health through scientifically validated nutritional solutions.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Soil Culture Solutions, LLC, founded in 2014 and based in Tampa, Florida, specializes in innovative genetic alteration technology. The company focuses on developing citrus trees using CRISPR editing techniques to enhance their resistance to severe diseases that threaten the citrus industry. Soil Culture Solutions holds exclusive licenses to patents from community universities, enabling it to employ precision breeding methods to effectively combat these critical infections in citrus crops.

Sequegenics is a technology company that specializes in genetic analysis through its fully automated cloud platform. The company has developed a novel approach utilizing augmented low-pass long-read next-generation sequencing (NGS) to identify structural variants and other complex types of genetic variations. By processing long-read NGS raw data, Sequegenics enables clients to efficiently minimize the time and cost associated with variant calling, while also enhancing turnaround time and scalability. This innovative platform supports researchers and healthcare professionals in their efforts to better understand genetic variations, ultimately contributing to advancements in genomic medicine.

Kodikaz Therapeutic Solutions is a biotechnology company focused on developing targeted cancer therapies that aim to provide durable cures while minimizing side effects associated with traditional treatments. The company has created the Zip-Code™ Technology platform, a pioneering cell-specific delivery system designed for a wide range of gene therapy applications. This innovative platform leverages endogenous human mechanisms to avoid the complications associated with viral delivery methods. By translating previously unknown cell-recognition and genomic integration mechanisms, Kodikaz enables the development of cell-specific gene transfer technologies tailored for various cancers, including pancreatic, myeloma, and colorectal. Through its research and development efforts, the company generates both in-vitro and in-vivo data to support the advancement of curative therapies in oncology.

Ancilia Biosciences is a biotechnology company focused on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components of the gut microbiome. By concentrating on enhancing healthy gut bacteria and their predatory phages, Ancilia develops therapeutic strains that can effectively combat chronic diseases in the fields of immunology and oncology. Additionally, the company is pioneering a new class of live biotherapeutics that allow for the precise targeting of phages or viruses known to induce lysis, thereby advancing treatment options in microbiome-related health conditions.

Stellate DNA, founded in 2020 and based in Cambridge, Massachusetts, specializes in proprietary DNA donor technology that enables the synthesis and production of single-strand DNA donors. The company's innovative platform employs clonal synthesis methods instead of traditional chemical synthesis, allowing for the customizable production of gene knock-in payloads. This approach ensures that Stellate DNA can achieve microgram to milligram scale production while maintaining well-controlled costs. Additionally, the technology supports medical professionals by ensuring minimal mutation rates and sequence uniformity, which are critical for various applications in genetic research and therapy.

Tacit Therapeutics is a biotechnology company focused on developing RNA-targeting treatments aimed at repairing mutated genes associated with devastating diseases. Founded in 2021 and located in South San Francisco, California, the company utilizes pre-existing components of human cells to create innovative and non-immunogenic approaches for gene modification. By offering a broadly applicable solution, Tacit Therapeutics enables biotechnology professionals to pursue effective treatments for genetic disorders that were previously deemed untreatable, thereby advancing the field of gene therapy.

InGateyGen is an agricultural biotechnology company focused on the development and production of hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that improve consumer health and safety. By addressing peanut allergies, InGateyGen is committed to enhancing the quality of life for individuals affected by these conditions.

Talus Bio is a biotechnology startup focused on drug discovery and development, particularly targeting challenging cancer transcription factors. The company employs an innovative approach that integrates functional proteomics, automated biology, and machine learning. Their MARMOT platform utilizes AI, advanced proteomics, synthetic chemistry, and computational biology to design and analyze drugs, proteins, and genomics. This platform is designed to advance drug development for gene regulation in oncology, aiming to create small-molecule therapies that can effectively control gene expression in cancer cells.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Founded in 2018, the company aims to transform the traditional methods of DNA production, which have remained largely unchanged for decades. Ansa's enzymatic approach promises to be faster, more accurate, and environmentally friendly compared to conventional chemical methods. This advanced technology facilitates the synthesis of gene-length oligonucleotides, enabling medical researchers to create synthetic genes efficiently. Ansa Biotechnologies' offerings are designed to support a wide range of applications in biological research, diagnostics, therapeutics, and biomanufacturing, ultimately accelerating innovation in the field of biotechnology.

NeyroblastGX is a biotechnology company based in Murrieta, California, founded in 2020. It specializes in developing theranostic products aimed at treating neurodegenerative and infectious diseases. The company's innovative product portfolio includes a blood-based biomarker diagnostic for Alzheimer's, genetically engineered dendritic cells designed to target custom-made human organoids for drug screening, and an oral supplement that enhances protective immunity. Through its comprehensive range of diagnostics, drugs, and therapies, NeyroblastGX is committed to providing effective solutions for patients facing life-threatening conditions.

Cobio Diagnostics is a biotechnology company founded in 2016 and located in Golden, Colorado. The company specializes in developing diagnostics for bacterial identification and phenotypic antibiotic resistance testing. Utilizing a phage-based immunoassay, Cobio Diagnostics' technology allows for the rapid identification of specific bacterial species and the assessment of antibiotic susceptibility, achieving results in under five hours. This innovative approach provides a faster and more targeted alternative to conventional diagnostic methods, enabling healthcare providers to make prompt and informed decisions regarding antibiotic treatments for patients with bacterial infections.

CasTag Biosciences is a biotechnology company that specializes in cell biology and regenerative medicine, with a focus on enhancing the speed of endogenous protein analysis. The company develops Adeno-associated virus kits that leverage a two-vector, clustered regularly interspaced short palindromic repeats-based gene editing technique known as homology-independent universal genome engineering. This innovative approach enables researchers to modify entire panels of proteins within cells and tissues, facilitating the study of novel genes across various experimental models. By providing advanced tools for protein analysis, CasTag Biosciences aims to accelerate scientific discovery and enhance understanding in the field of genetics.

Cornerstone Genomics, established in 2017 and based in Frederick, Maryland, specializes in providing expert guidance on the application of genomic tools in human disease research, biomedicine, veterinary sciences, and wildlife conservation. The company operates a biotechnology platform that houses proprietary DNA and protein sequence databases, along with applications designed to meticulously filter, annotate, and predict the functional impact of genetic variants. This precision enables researchers to accurately identify disease-causing genetic changes, facilitating the development of targeted therapies and gene therapies for inherited diseases.

Jupiter Therapeutics is a biotechnology company specializing in the development of cell-membrane-based therapeutics. It employs cell engineering techniques to create customized vesicles aimed at advancing immuno-oncology and gene therapy. By leveraging a synthetic biology approach, Jupiter Therapeutics facilitates the rapid design and synthesis of a diverse pipeline of therapeutic assets that address critical areas such as cancer and autoimmunity. The company allows medical researchers to utilize insights from cell-membrane studies to enhance the effectiveness of CAR T-cells and bi-specific antibodies, thereby contributing to innovative treatments in the biotherapeutics field.

GRO Biosciences is a biotechnology company focused on developing advanced protein therapeutics to address various health conditions, including diabetes, growth disorders, and autoimmunity. The company employs innovative technologies in computational protein design and synthetic biology, which enable it to create genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This approach enhances the properties of the proteins, resulting in increased potency, stability, and targeted delivery. Through its technology platform, GRO Biosciences aims to provide improved treatment options across multiple disease classes, contributing to advancements in medical therapeutics.

Acrigen Biosciences is focused on advancing gene editing technologies to enhance the safety and efficiency of CRISPR-Cas based systems. Founded in 2019 and headquartered in Berkeley, California, the company develops precision gene editing solutions aimed at producing effective and safe in vivo drug therapies for various diseases. Acrigen's innovations include Acro proteins that regulate the CRISPR-Cas gene editing process, along with a bioinformatics discovery software platform designed to identify suitable CRISPR systems for human therapeutic applications. By improving anti-CRISPR proteins and optimizing genetic therapies, Acrigen aims to contribute significantly to the field of medicine and the treatment of debilitating conditions.

Inherent Biosciences is a molecular diagnostics company focused on transforming the traditional trial and error approach in medicine. The company leverages its innovative epigenetic medicine platform to address various health challenges by identifying gene dysregulation and its associated pathways. By translating biological insights into actionable information, Inherent Biosciences aims to enhance treatment strategies for conditions such as pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. This approach not only guides healthcare professionals in managing complex diseases but also seeks to provide personalized insights that empower patients in their health journeys.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Plastomics Inc. is a biotechnology company that specializes in chloroplast genetic engineering to enhance crop performance and nutritional quality. Founded in 2016 and based in Saint Louis, Missouri, the company utilizes a proprietary technology platform to insert beneficial traits into the chloroplasts of plant cells. This innovative approach allows seed companies to develop advanced biotech crops with a diverse array of traits while addressing current industry challenges. Plastomics' technology not only eliminates cross-pollination but also facilitates unique maternal inheritance, significantly reducing breeding timelines and associated costs. By focusing on gene stacking and rapid breeding, Plastomics aims to improve yield production and contribute to the advancement of agricultural biotechnology.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Protabit is a protein engineering company focused on developing innovative solutions for industrial, agricultural, and healthcare applications. The company utilizes a proprietary platform that integrates computational modeling, high-throughput screening, and directed evolution to enhance the diversity of protein sequences. This advanced approach allows Protabit to create novel proteins tailored to meet specific client needs. The company's efforts are further strengthened through a strategic partnership with the Monsanto Company and the California Institute of Technology, positioning Protabit at the forefront of the protein design field.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally invented at Cornell University, Inso Biosciences enhances the efficiency of processing cellular material. The company's platform is designed to facilitate genomic analysis, including applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. By enabling healthcare and biotechnology companies to effectively separate and isolate cellular components, Inso Biosciences aims to transform the landscape of biological sample preparation.

LEAH Laboratories specializes in developing innovative gene-editing technologies aimed at treating cancer in dogs, particularly B-cell lymphoma. The company utilizes precision gene editing to reprogram T immune cells with Chimeric Antigen Receptors (CAR), creating CAR T cells that can specifically target and eliminate cancerous cells while minimizing off-target effects commonly associated with traditional chemotherapy. By harnessing the natural capabilities of the canine immune system, LEAH Laboratories provides a novel approach to cancer treatment, offering hope to pet owners and veterinarians in their fight against this challenging disease. Based in the United States, LEAH Labs is committed to advancing medical therapies for canine health.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally invented at Cornell University, Inso Biosciences enhances the efficiency of processing cellular material. The company's platform is designed to facilitate genomic analysis, including applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. By enabling healthcare and biotechnology companies to effectively separate and isolate cellular components, Inso Biosciences aims to transform the landscape of biological sample preparation.

Yesse Technologies is a biotechnology company focused on developing an innovative genetic biosensing platform that digitizes the sense of smell. The company utilizes advanced nanotechnology and the biology of real noses to create a unique solution involving genetically modified super sniffer mice, which contribute to a live, human nose-on-a-chip. This technology aims to identify and catalog every conceivable odor, from fragrances used in perfumery to those linked with various diseases. By merging molecular biology, genetic manipulation, and olfaction, Yesse Technologies is positioned to transform odor detection and identification, providing valuable insights across various fields.

Parse Biosciences is a biotechnology company specializing in single-cell analysis and sequencing solutions. Founded in 2018 and based in Seattle, Washington, the company focuses on developing innovative technologies that simplify the sequencing process for researchers. By employing combinatorial cDNA barcoding directly within cells, Parse Biosciences eliminates the necessity for complex and costly microfluidic instruments. This technology allows for the fixing, freezing, and storage of samples, enabling researchers to conduct experiments with samples collected on different dates in a single run. This capability enhances sample handling and minimizes errors, ultimately improving the accuracy of results. The company aims to increase gene detection in individual cells while addressing common challenges associated with single-cell sequencing, thereby advancing research in various scientific fields.

Design Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Solana Beach, California, focused on developing innovative therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company specializes in a novel class of small-molecule gene-targeted chimera therapeutics known as GeneTACTM molecules, which aim to modify disease progression by addressing the root causes of these conditions. Its lead program targets Friedreich’s ataxia, while additional efforts are directed toward conditions such as Fuchs endothelial corneal dystrophy and other degenerative diseases like Fragile X syndrome and myotonic dystrophy. Since its incorporation in 2017, Design Therapeutics has been dedicated to advancing its therapeutic candidates to potentially transform treatment options for patients suffering from these inherited disorders.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Founded in 2018, the company aims to transform the traditional methods of DNA production, which have remained largely unchanged for decades. Ansa's enzymatic approach promises to be faster, more accurate, and environmentally friendly compared to conventional chemical methods. This advanced technology facilitates the synthesis of gene-length oligonucleotides, enabling medical researchers to create synthetic genes efficiently. Ansa Biotechnologies' offerings are designed to support a wide range of applications in biological research, diagnostics, therapeutics, and biomanufacturing, ultimately accelerating innovation in the field of biotechnology.

Kytopen, established in 2017 and based in Cambridge, Massachusetts, specializes in the development of a cell therapy platform. This platform facilitates the non-viral delivery of molecules into challenging-to-transfect immune cells, making the process easier, faster, and more cost-effective. The company's proprietary Flowfect™ technology combines microfluidics and automation, enabling researchers to explore new biological discoveries and develop more affordable cell and gene therapies.

InGateyGen is an agricultural biotechnology company focused on the development and production of hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that improve consumer health and safety. By addressing peanut allergies, InGateyGen is committed to enhancing the quality of life for individuals affected by these conditions.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

GenEdit Inc., established in 2016 and headquartered in Berkeley, California, specializes in developing innovative genome editing tools. The company's core technology is CRISPR/Cas9, which enables precise therapeutic gene editing. GenEdit has further advanced this field by creating the NanoGalaxy™ platform, a proprietary non-viral delivery system that efficiently transports CRISPR/Cas9 to target tissues, overcoming previous delivery challenges. This platform systematically screens a library of nanoparticles to ensure safer and more effective delivery, making therapeutic gene editing easier, faster, and more accurate than traditional methods. GenEdit's ultimate goal is to facilitate the cure of previously incurable genetic diseases by providing physicians with powerful tools for gene therapy.

GRO Biosciences is a biotechnology company focused on developing advanced protein therapeutics to address various health conditions, including diabetes, growth disorders, and autoimmunity. The company employs innovative technologies in computational protein design and synthetic biology, which enable it to create genomically recoded strains of bacteria capable of incorporating non-standard amino acids into proteins. This approach enhances the properties of the proteins, resulting in increased potency, stability, and targeted delivery. Through its technology platform, GRO Biosciences aims to provide improved treatment options across multiple disease classes, contributing to advancements in medical therapeutics.

Rumi Scientific is a research-based company focused on developing medications and innovative treatments for genetic illnesses affecting the central nervous system, with a particular emphasis on Huntington's Disease. The company utilizes a proprietary human organoid platform that simulates human development in vitro, integrating genetic models created through gene editing with multi-cellular self-organization to generate defined diseased embryonic tissues. This platform facilitates drug discovery and high-throughput screening, allowing for the identification of effective treatments using advanced artificial intelligence techniques. By prioritizing synthetic human embryology in both normal and pathological contexts, Rumi Scientific aims to advance therapeutic options for numerous genetic disorders that currently lack viable cures, striving to enhance treatment success rates and improve patient outcomes.

Soil Culture Solutions, LLC, founded in 2014 and based in Tampa, Florida, specializes in innovative genetic alteration technology. The company focuses on developing citrus trees using CRISPR editing techniques to enhance their resistance to severe diseases that threaten the citrus industry. Soil Culture Solutions holds exclusive licenses to patents from community universities, enabling it to employ precision breeding methods to effectively combat these critical infections in citrus crops.

Cornerstone Genomics, established in 2017 and based in Frederick, Maryland, specializes in providing expert guidance on the application of genomic tools in human disease research, biomedicine, veterinary sciences, and wildlife conservation. The company operates a biotechnology platform that houses proprietary DNA and protein sequence databases, along with applications designed to meticulously filter, annotate, and predict the functional impact of genetic variants. This precision enables researchers to accurately identify disease-causing genetic changes, facilitating the development of targeted therapies and gene therapies for inherited diseases.

BioInfoExperts specializes in comprehensive molecular surveillance services aimed at understanding infectious disease dynamics and monitoring pathogens. The company provides a range of services, including genomic sequencing, extraction of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), and advanced data analytics. Additionally, BioInfoExperts offers cloud-based data visualizations, facilitating efficient research and development of diagnostic tests for various infectious diseases. With a focus on supporting laboratory services, the company enables clients to enhance their capabilities in pathogen surveillance and analysis.

Parabricks is a developer of high-performance genomic analysis software that utilizes GPU acceleration and machine learning to process next-generation sequencing data. The company's innovative technology allows for the analysis of an entire human genome in under an hour, drastically reducing the time required for genomic processing from days to minutes. This capability not only enhances throughput for healthcare facilities but also enables cost-effective genomic analysis, whether conducted in the cloud or on-premise servers. By facilitating personalized treatment based on genomic variations, Parabricks is poised to transform healthcare practices, making rapid and precise genomic insights accessible for patient care.

Novome Biotechnologies, Inc. is a biotechnology company specializing in the engineering of gut bacteria to create innovative therapies for chronic diseases. Established in 2015 and located in South San Francisco, California, Novome has developed a pioneering platform for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs). This platform allows for the precise delivery of therapeutic activities aimed at treating conditions such as hyperoxaluria, with a focus on creating a bacterial strain that can degrade oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology capabilities to explore additional therapeutic indications, aiming to improve long-term health outcomes for patients through its living therapeutics.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Mission Bio, Inc. is a biotechnology company focused on advancing the study of cellular heterogeneity through its innovative Tapestri Platform, which is the first single-cell multi-omics platform. This platform allows for the simultaneous analysis of genotype and phenotype from individual cells, enabling precise detection of variations in disease progression and treatment responses. Utilizing proprietary microfluidic droplet technology, Mission Bio provides targeted solutions for high-impact applications in fields such as oncology, hematology, and genome editing. The company also offers Tapestri Designer, a cloud-based tool for creating custom single-cell DNA panels, enhancing its capabilities in research and clinical settings. Founded in 2011 and based in South San Francisco, California, Mission Bio was previously known as Torrent Bio, Inc. before rebranding in 2013.

Parabricks is a developer of high-performance genomic analysis software that utilizes GPU acceleration and machine learning to process next-generation sequencing data. The company's innovative technology allows for the analysis of an entire human genome in under an hour, drastically reducing the time required for genomic processing from days to minutes. This capability not only enhances throughput for healthcare facilities but also enables cost-effective genomic analysis, whether conducted in the cloud or on-premise servers. By facilitating personalized treatment based on genomic variations, Parabricks is poised to transform healthcare practices, making rapid and precise genomic insights accessible for patient care.

Kytopen, established in 2017 and based in Cambridge, Massachusetts, specializes in the development of a cell therapy platform. This platform facilitates the non-viral delivery of molecules into challenging-to-transfect immune cells, making the process easier, faster, and more cost-effective. The company's proprietary Flowfect™ technology combines microfluidics and automation, enabling researchers to explore new biological discoveries and develop more affordable cell and gene therapies.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, a targeted cancer therapy using gene-engineered allogeneic CAR-NK cells designed to eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A for treating hepatocellular carcinoma.

Yesse Technologies is a biotechnology company focused on developing an innovative genetic biosensing platform that digitizes the sense of smell. The company utilizes advanced nanotechnology and the biology of real noses to create a unique solution involving genetically modified super sniffer mice, which contribute to a live, human nose-on-a-chip. This technology aims to identify and catalog every conceivable odor, from fragrances used in perfumery to those linked with various diseases. By merging molecular biology, genetic manipulation, and olfaction, Yesse Technologies is positioned to transform odor detection and identification, providing valuable insights across various fields.

CrossLife Technologies is a life science company focused on developing and commercializing molecular diagnostics for both infectious and non-communicable diseases. The firm specializes in creating diagnostic tools that utilize nucleic acid and DNA technologies to detect a wide range of infectious pathogens, including HIV, malaria, chikungunya, and influenza. Their innovative approach allows for direct detection of these pathogens from various sample types without the need for sample preparation, polymerase chain reaction, or specialized instrumentation. By advancing these diagnostic technologies, CrossLife Technologies aims to reduce suffering and improve health outcomes for patients.

Inscent is a technology development, gene discovery, and functional genomics company that identified novel molecules to control insect pests. Key areas of interest include the prevention of disease transmission to humans and the development of environmentally friendly products for public health, agricultural, domestic, and industrial applications.

Navipoint Genomics is a bioinformatics analysis software developer headquartered in Chicago, Illinois, and founded in 2015. The company specializes in the analysis of entire human genomes, providing tools that enhance the speed and efficiency of large-scale genomic analysis. Its software facilitates the transfer and examination of full human genomes, significantly reducing analysis time. Additionally, Navipoint Genomics develops a pipeline that enables the investigation of gene expression changes and the detection of fusion transcripts at the whole-transcriptome level. This capability allows clients to achieve improved reporting quality, characterized by high confidence values and fewer false negatives in their genomic analyses.

enEvolv, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in engineering and licensing microorganisms such as bacteria, yeast, and algae for diverse applications across industries including specialty chemicals, food, energy, personal care, and pharmaceuticals. Established in 2011, the company focuses on developing cost-effective and sustainable solutions to meet the growing global demand for critical resources driven by population growth and increased economic prosperity. enEvolv collaborates with various organizations to create novel microorganisms and enhance existing strains to boost production yields and improve product quality. Utilizing a proprietary genome engineering platform based on advanced techniques developed at Harvard, enEvolv accelerates microbial evolution to enable precise genomic edits, offering significant advantages in speed, cost, and engineering capabilities. As of March 2020, enEvolv operates as a subsidiary of Zymergen, Inc.

Varigen Biosciences is developing new technologies for capturing and expressing natural product pathways. Learn about our DNAtrap™ custom cloning service which delivers verified clones of your DNA target (up to 100 kb) in just 10 days at http://varigenbiosciences.com/dnatrap-custom-cloning-service/. Learn about how our BigDNA™ metagenomics libraries can revolutionize natural product discovery at http://varigenbiosciences.com/products/.

Parabricks is a developer of high-performance genomic analysis software that utilizes GPU acceleration and machine learning to process next-generation sequencing data. The company's innovative technology allows for the analysis of an entire human genome in under an hour, drastically reducing the time required for genomic processing from days to minutes. This capability not only enhances throughput for healthcare facilities but also enables cost-effective genomic analysis, whether conducted in the cloud or on-premise servers. By facilitating personalized treatment based on genomic variations, Parabricks is poised to transform healthcare practices, making rapid and precise genomic insights accessible for patient care.

BioInfoExperts specializes in comprehensive molecular surveillance services aimed at understanding infectious disease dynamics and monitoring pathogens. The company provides a range of services, including genomic sequencing, extraction of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), and advanced data analytics. Additionally, BioInfoExperts offers cloud-based data visualizations, facilitating efficient research and development of diagnostic tests for various infectious diseases. With a focus on supporting laboratory services, the company enables clients to enhance their capabilities in pathogen surveillance and analysis.

Novome Biotechnologies, Inc. is a biotechnology company specializing in the engineering of gut bacteria to create innovative therapies for chronic diseases. Established in 2015 and located in South San Francisco, California, Novome has developed a pioneering platform for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs). This platform allows for the precise delivery of therapeutic activities aimed at treating conditions such as hyperoxaluria, with a focus on creating a bacterial strain that can degrade oxalate to help prevent kidney stone formation. The company is also expanding its synthetic biology capabilities to explore additional therapeutic indications, aiming to improve long-term health outcomes for patients through its living therapeutics.

InGateyGen is an agricultural biotechnology company focused on the development and production of hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that improve consumer health and safety. By addressing peanut allergies, InGateyGen is committed to enhancing the quality of life for individuals affected by these conditions.

Modular Genetics, Inc. is a biotechnology company based in Woburn, Massachusetts, founded in 2000. The company specializes in designing and developing engineered microorganisms that synthesize chemicals from renewable raw materials, such as sugar. By utilizing a proprietary automated gene engineering system, Modular Genetics focuses on sustainable chemistry, enabling industries to accelerate product development, reduce costs, and facilitate the simultaneous creation of multiple products.

T3S Technologies, Inc. is a biotechnology company based in Salt Lake City, Utah, that specializes in producing proteins from bacteria. Incorporated in 2015, the company utilizes its expertise in genetics and biochemistry to develop proprietary technologies for the genetic engineering of bacterial cells. This enables the expression and optimization of difficult-to-express recombinant protein products, which supports researchers in their efforts to facilitate protein production for various applications, including the treatment of chronic diseases. Through its innovative approach, T3S Technologies aims to advance the field of protein therapeutics.

Mission Bio, Inc. is a biotechnology company focused on advancing the study of cellular heterogeneity through its innovative Tapestri Platform, which is the first single-cell multi-omics platform. This platform allows for the simultaneous analysis of genotype and phenotype from individual cells, enabling precise detection of variations in disease progression and treatment responses. Utilizing proprietary microfluidic droplet technology, Mission Bio provides targeted solutions for high-impact applications in fields such as oncology, hematology, and genome editing. The company also offers Tapestri Designer, a cloud-based tool for creating custom single-cell DNA panels, enhancing its capabilities in research and clinical settings. Founded in 2011 and based in South San Francisco, California, Mission Bio was previously known as Torrent Bio, Inc. before rebranding in 2013.

Serotiny, Inc. is a biotechnology company based in San Francisco, California, focused on the design and development of multi-domain proteins and therapies aimed at treating cancers and genetic disorders. Founded in 2014, Serotiny leverages a unique platform that integrates synthetic biology with advanced informatics to facilitate the rational design of proteins. The company specializes in creating therapeutic proteins for CAR T-cell therapies and other cellular therapies. By harmonizing computational protein design, high-throughput cellular assays, and next-generation sequencing, Serotiny employs a cross-disciplinary approach that incorporates expertise from immunology, machine learning, software engineering, and bioinformatics. This innovative methodology enables the development of gene and cell therapies with improved safety and efficacy through novel control mechanisms and engineered functionalities.

Protabit is a protein engineering company focused on developing innovative solutions for industrial, agricultural, and healthcare applications. The company utilizes a proprietary platform that integrates computational modeling, high-throughput screening, and directed evolution to enhance the diversity of protein sequences. This advanced approach allows Protabit to create novel proteins tailored to meet specific client needs. The company's efforts are further strengthened through a strategic partnership with the Monsanto Company and the California Institute of Technology, positioning Protabit at the forefront of the protein design field.

Aperiomics is a biotechnology company based in Sterling, Virginia, specializing in pathogen detection services across animal screening, agricultural testing, and human diagnostics industries. Founded in 2013, the company uses advanced genomics and informatics technologies to detect viral, bacterial, fungal, and parasitic pathogens through a single test. Aperiomics employs sequencing technologies and Bayesian statistics to analyze blood, tissue, and stool samples sent by customers. The company's unique approach, supported by the National Science Foundation, involves Deep Shotgun Metagenomic Sequencing and a comprehensive database of over 37,000 microbes. This enables medical professionals to identify infections that other tests may miss, leading to more accurate diagnoses and improved clinical outcomes for patients who have often been ill for extended periods without a clear cause.

Epicrop Technologies, Inc. is a biotechnology company based in Lincoln, Nebraska, founded in 2013. The company specializes in developing innovative epigenetic technology aimed at enhancing crop yields and crop development. Epicrop's technology focuses on improving abiotic stress tolerance across all plant species, providing farmers with the tools to increase productivity while maintaining lower crop prices. In addition to its core technology, Epicrop also offers support services that assist in optimizing crop production, thereby contributing to sustainable agricultural practices.

Knudra Transgenics, LLC, founded in 2009 and located in Murray, Utah, specializes in the research, development, and production of deoxyribonucleic acid (DNA) mixes and plasmids tailored for the biomedical industry. The company provides a custom transgenics production service, focusing on organisms such as Caenorhabditis elegans (C. elegans). Knudra operates as a subsidiary of NemaMetrix, Inc., and offers a cloud-based genome engineering platform that enables biotechnologists to test the genome compositions of various organisms by injecting external reagents.

Mission Bio, Inc. is a biotechnology company focused on advancing the study of cellular heterogeneity through its innovative Tapestri Platform, which is the first single-cell multi-omics platform. This platform allows for the simultaneous analysis of genotype and phenotype from individual cells, enabling precise detection of variations in disease progression and treatment responses. Utilizing proprietary microfluidic droplet technology, Mission Bio provides targeted solutions for high-impact applications in fields such as oncology, hematology, and genome editing. The company also offers Tapestri Designer, a cloud-based tool for creating custom single-cell DNA panels, enhancing its capabilities in research and clinical settings. Founded in 2011 and based in South San Francisco, California, Mission Bio was previously known as Torrent Bio, Inc. before rebranding in 2013.

GlobalBio specializes in therapeutic antibody engineering. The company, which was founded in 2014 with funds from the National Science Foundation, is based in Brookline, Massachusetts.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

enEvolv, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in engineering and licensing microorganisms such as bacteria, yeast, and algae for diverse applications across industries including specialty chemicals, food, energy, personal care, and pharmaceuticals. Established in 2011, the company focuses on developing cost-effective and sustainable solutions to meet the growing global demand for critical resources driven by population growth and increased economic prosperity. enEvolv collaborates with various organizations to create novel microorganisms and enhance existing strains to boost production yields and improve product quality. Utilizing a proprietary genome engineering platform based on advanced techniques developed at Harvard, enEvolv accelerates microbial evolution to enable precise genomic edits, offering significant advantages in speed, cost, and engineering capabilities. As of March 2020, enEvolv operates as a subsidiary of Zymergen, Inc.

TeselaGen Biotechnology, established in 2011 and headquartered in San Francisco, specializes in DNA design and assembly tools for biological research. The company provides a cloud-based solution enabling combinatorial gene design and editing, which includes tools for visualizing, editing, and annotating genetic sequences, constructing novel gene constructs, optimizing assembly protocols, and validating design variants.

TeselaGen Biotechnology, established in 2011 and headquartered in San Francisco, specializes in DNA design and assembly tools for biological research. The company provides a cloud-based solution enabling combinatorial gene design and editing, which includes tools for visualizing, editing, and annotating genetic sequences, constructing novel gene constructs, optimizing assembly protocols, and validating design variants.

TeselaGen Biotechnology, established in 2011 and headquartered in San Francisco, specializes in DNA design and assembly tools for biological research. The company provides a cloud-based solution enabling combinatorial gene design and editing, which includes tools for visualizing, editing, and annotating genetic sequences, constructing novel gene constructs, optimizing assembly protocols, and validating design variants.

Insilicom provides advanced next-generation sequencing data analysis solutions for cancer research biomarker discovery. The company was founded in 2013 and is headquartered in Tallahassee, Florida.

Advirna is a private biotechnology company focused on advancing innovative approaches for the efficient delivery of polynucleotides in vivo. The company specializes in self-deliverable RNA interference (RNAi) technology, which enables precise regulation of gene activity within living cells. This breakthrough allows for effective gene knockdown in challenging cell lines, both ex vivo and in vivo, facilitating extensive research and manipulation of gene function. Advirna’s technology enhances the delivery of RNAi across various cell types and specific organs, supporting a wide range of applications in genetic research and therapeutic development.

Aperiomics is a biotechnology company based in Sterling, Virginia, specializing in pathogen detection services across animal screening, agricultural testing, and human diagnostics industries. Founded in 2013, the company uses advanced genomics and informatics technologies to detect viral, bacterial, fungal, and parasitic pathogens through a single test. Aperiomics employs sequencing technologies and Bayesian statistics to analyze blood, tissue, and stool samples sent by customers. The company's unique approach, supported by the National Science Foundation, involves Deep Shotgun Metagenomic Sequencing and a comprehensive database of over 37,000 microbes. This enables medical professionals to identify infections that other tests may miss, leading to more accurate diagnoses and improved clinical outcomes for patients who have often been ill for extended periods without a clear cause.

Parabon NanoLabs Inc. is a biotechnology company based in Reston, Virginia, specializing in the development of innovative nanopharmaceuticals and advanced forensic products. Utilizing a cutting-edge nanoscale development platform, the company designs multi-functional macromolecules aimed at treating various types of cancer, including brain, lung, and breast cancers. Additionally, Parabon NanoLabs develops and licenses its macromolecules for diverse applications, such as nano-sensors for bioweapons defense, DNA biometrics, and consumer product enhancements. The company's team comprises experts in fields like bioinformatics, oncology, chemistry, and computer science, which allows it to create next-generation therapeutics and forensic tools by harnessing the power of DNA. As a small business recognized by the U.S. Small Business Administration, Parabon NanoLabs has received multiple grants and contracts through the Small Business Innovation Research and Small Business Technology Transfer programs.

Modular Genetics, Inc. is a biotechnology company based in Woburn, Massachusetts, founded in 2000. The company specializes in designing and developing engineered microorganisms that synthesize chemicals from renewable raw materials, such as sugar. By utilizing a proprietary automated gene engineering system, Modular Genetics focuses on sustainable chemistry, enabling industries to accelerate product development, reduce costs, and facilitate the simultaneous creation of multiple products.

Protabit is a protein engineering company focused on developing innovative solutions for industrial, agricultural, and healthcare applications. The company utilizes a proprietary platform that integrates computational modeling, high-throughput screening, and directed evolution to enhance the diversity of protein sequences. This advanced approach allows Protabit to create novel proteins tailored to meet specific client needs. The company's efforts are further strengthened through a strategic partnership with the Monsanto Company and the California Institute of Technology, positioning Protabit at the forefront of the protein design field.

Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, aimed at creating DNA-based products across various industries. Founded in 2013, the company has developed a proprietary method that allows for the reliable, affordable, and sustainable production of long, high-quality, sequence-specific DNA. This innovative technology is designed to support advancements in industrial synthetic biology, personalized therapeutics, precision diagnostics, and has potential applications in information storage and nanotechnology. With a strong executive and scientific team, as well as a robust intellectual property portfolio, Molecular Assemblies is positioned to enhance the capabilities of researchers and contribute to the evolution of DNA-based applications.

The J. Craig Venter Institute is a prominent organization in genomic research, formed in 2006 through the merger of several legacy institutions, including The Institute for Genomic Research and The Center for the Advancement of Genomics. With over 400 scientists and staff, the institute operates from locations in Rockville, Maryland, and San Diego, California, encompassing more than 250,000 square feet of laboratory space. The institute has been at the forefront of genomic advancements for over two decades, initiated by Dr. J. Craig Venter and his teams, who pioneered techniques such as expressed sequence tags and contributed to the sequencing of the first free-living organism, Haemophilus influenzae. The institute's research spans a wide array of fields including genomics medicine, infectious diseases, mammalian genomics, microbial and environmental genomics, and synthetic biology. Recent projects include the sequencing of the first diploid human genome, global ocean sampling expeditions, and the analysis of various infectious disease agents. The institute aims to enhance human health and environmental understanding through its innovative research efforts.

Protabit is a protein engineering company focused on developing innovative solutions for industrial, agricultural, and healthcare applications. The company utilizes a proprietary platform that integrates computational modeling, high-throughput screening, and directed evolution to enhance the diversity of protein sequences. This advanced approach allows Protabit to create novel proteins tailored to meet specific client needs. The company's efforts are further strengthened through a strategic partnership with the Monsanto Company and the California Institute of Technology, positioning Protabit at the forefront of the protein design field.

Inscent is a technology development, gene discovery, and functional genomics company that identified novel molecules to control insect pests. Key areas of interest include the prevention of disease transmission to humans and the development of environmentally friendly products for public health, agricultural, domestic, and industrial applications.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, that specializes in cellular engineering and genome editing solutions using CRISPR technology. Incorporated in 2011, the company has developed a CRISPR-Cas gene editing platform that allows precise modifications to DNA, which is applicable across various fields including human and animal therapeutics, agricultural biotechnology, and industrial biotech. Caribou's innovative approach aims to create transformative therapies, particularly in the development of allogeneic CAR-T and CAR-NK cell therapies, targeting serious diseases. The company focuses on advancing its pipeline of next-generation genome-edited cell therapies while also contributing to basic and applied biological research.

enEvolv, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in engineering and licensing microorganisms such as bacteria, yeast, and algae for diverse applications across industries including specialty chemicals, food, energy, personal care, and pharmaceuticals. Established in 2011, the company focuses on developing cost-effective and sustainable solutions to meet the growing global demand for critical resources driven by population growth and increased economic prosperity. enEvolv collaborates with various organizations to create novel microorganisms and enhance existing strains to boost production yields and improve product quality. Utilizing a proprietary genome engineering platform based on advanced techniques developed at Harvard, enEvolv accelerates microbial evolution to enable precise genomic edits, offering significant advantages in speed, cost, and engineering capabilities. As of March 2020, enEvolv operates as a subsidiary of Zymergen, Inc.

Knudra Transgenics, LLC, founded in 2009 and located in Murray, Utah, specializes in the research, development, and production of deoxyribonucleic acid (DNA) mixes and plasmids tailored for the biomedical industry. The company provides a custom transgenics production service, focusing on organisms such as Caenorhabditis elegans (C. elegans). Knudra operates as a subsidiary of NemaMetrix, Inc., and offers a cloud-based genome engineering platform that enables biotechnologists to test the genome compositions of various organisms by injecting external reagents.

Primordial Genetics Inc. is a biotechnology company based in San Diego, California, founded in 2011. The company specializes in developing microbes and enzymes for pharmaceutical and industrial manufacturing, as well as agriculture. It utilizes whole-genome synthetic biology tools to create production organisms and industrial enzymes. One of its key innovations is the Function Generator, a combinatorial gain-of-function genetic technology that enhances the tolerances, productivities, and growth characteristics of microbial organisms. This technology supports the renewable production of chemicals, fuels, pharmaceuticals, and other commercially valuable compounds. Primordial Genetics' solutions are applicable across various industries, including therapeutic protein production, industrial enzyme development, novel protein discovery, and the creation of renewable fuels and chemicals.

Digital World Biology develops and sells mobile applications and instructional materials that allow students to conduct molecular biology research. The apps can be used by elementary school students to work with DNA structures and molecules. They bring bioinformatics out of the lab and into the classroom. The company also provides professional development for college instructors and school teachers, as a genomics consulting service.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Da Yu Protein Sciences is a research driven biotechnology company developing technologies and services for drug discovery and the bioprocessing industry. Their client base includes biopharmaceutical companies, pharmaceutical companies, and research organizations pursuing drug discovery and development.

Modular Genetics, Inc. is a biotechnology company based in Woburn, Massachusetts, founded in 2000. The company specializes in designing and developing engineered microorganisms that synthesize chemicals from renewable raw materials, such as sugar. By utilizing a proprietary automated gene engineering system, Modular Genetics focuses on sustainable chemistry, enabling industries to accelerate product development, reduce costs, and facilitate the simultaneous creation of multiple products.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Cambrian Genomics specializes in manufacturing hardware for laser printing DNA sequences. They serve both academic and industrial researchers who require high-quality, sequence-verified DNA strands for their studies or applications, capitalizing on the existing global market valued at over $1 billion annually.

Akonni Biosystems, Inc. is a biotechnology company specializing in molecular diagnostics, focusing on the development and manufacture of integrated systems for clinical and life science research markets. Founded in 2003 and headquartered in Frederick, Maryland, the company offers a range of products, including the TruDiagnosis point-of-care testing platform, which allows healthcare professionals to analyze infectious diseases effectively. Its product lineup features TruTip kits for DNA and RNA extraction, TruArray tests for multiplexed molecular diagnostics from various clinical samples, and various MDx instrument platforms such as microarray readers and thermal cyclers. The company’s technologies are particularly relevant for diagnosing infectious diseases, pharmacogenomics, oncology, Alzheimer’s, and cardiovascular conditions, addressing complex health issues including multi-drug-resistant infections.

InnoGenomics Technologies specializes in genetic testing solutions, offering a comprehensive range of services that includes DNA quantification, STR genotyping, genotyping and gene expression assays. The company has developed a patented technology that is versatile and applicable in various fields such as forensic identification, missing person investigations, and the establishment of relationships and ancestral ethnic-geographic connections. Additionally, InnoGenomics provides biological sample research and development, validation services, and training to support its genetic testing capabilities. This combination of innovative technology and diverse service offerings positions InnoGenomics as a key player in the genetic testing industry.

TeselaGen Biotechnology, established in 2011 and headquartered in San Francisco, specializes in DNA design and assembly tools for biological research. The company provides a cloud-based solution enabling combinatorial gene design and editing, which includes tools for visualizing, editing, and annotating genetic sequences, constructing novel gene constructs, optimizing assembly protocols, and validating design variants.

Knudra Transgenics, LLC, founded in 2009 and located in Murray, Utah, specializes in the research, development, and production of deoxyribonucleic acid (DNA) mixes and plasmids tailored for the biomedical industry. The company provides a custom transgenics production service, focusing on organisms such as Caenorhabditis elegans (C. elegans). Knudra operates as a subsidiary of NemaMetrix, Inc., and offers a cloud-based genome engineering platform that enables biotechnologists to test the genome compositions of various organisms by injecting external reagents.